There are 2789 resources available
1654P - A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
Presenter: Zoran Andric
Session: ePoster Display
1655P - Real-world outcome of patients with relapsed or refractory small cell lung cancer treated with checkpoint inhibitors in Tertiary Care Centers across Germany
Presenter: Jan Stratmann
Session: ePoster Display
1539P - Sarcomas in the Dutch LFS population: Data from the national screening of TP53 germline mutation carriers at the Netherlands Cancer Institute
Presenter: Gijsbrecht de Wit
Session: ePoster Display
1657P - Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study
Presenter: Bing Xia
Session: ePoster Display
1658P - Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)
Presenter: Andrea Plaja
Session: ePoster Display
1659P - Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer
Presenter: Ning Yan
Session: ePoster Display
1660P - Changes in the pattern of diagnosis and treatment of patients with SCLC in the last 20 years
Presenter: Alejandro Rios Hoyo
Session: ePoster Display
1546P - Therapeutic strategies for uterine PEComas
Presenter: Chiara Cimmino
Session: ePoster Display
1547P - Trabectedin in soft-tissue sarcoma patients in Italy: Analysis of real-world data from a national registry
Presenter: Bruno Vincenzi
Session: ePoster Display